<article id="sc_popup_01" class="slide" data-ag-slide-name="sc_popup_01">
    <div class="basic">
      <h1 data-ag-editable="Main Title">Neulasta<sup>速</sup> is a well-established molecule</h1>
        <!-- Content here -->
        <div id="center-content">
            <div class="blocks left">
                 <h4>Neulasta<sup>速</sup></h4>
                <p>Built around filgrastim, an established G-CSF<sup>[Molineux 2004]</sup></p>
            </div>
            <div  class="blocks right">
                <h4>Lipegfilgrastim</h4>
                <p>Originator compound built around a filgrastim intermediate, XM21<sup>[Lipeg EPAR]</sup></p>
            </div>



              <div class="blocks" id="three">
                <h4>Comprehensive body of evidence</h4>
                <p>More than 30 clinical trials comprising more than 9 tumour types in numerous chemotherapy regimens and FN risk groups<sup>[Gregory 2010]</sup></p>
            </div>
            <div  class="blocks" id="four">
                <h4>Limited body of evidence</h4>
                <p>Only 2 pivotal clinical trials, 1 of which showed no significant risk reduction with lipegfilgrastim vs placebo for the primary endpoint of
                    FN incidence<sup>[Lonquex SmPC]</sup></p>
            </div>

            <div class="blocks left" id="firstdesc">
                <p>N-terminus pegylation, to reduce interference with receptor binding, and to provide homogenous pegylation<sup>[Molineux 1999] [Molineux 2004] [Layton 2001] [Tamada 2006]</sup></p>
            </div>

            <div class="blocks left" id="secdesc">
                <p>20 kDa linear PEG (polyethylene glycol), gave optimal activity in comparison with other pegylation options<sup>[Molineux 2004]</sup></p>
            </div>

            <div class="blocks left" id="thirdesc">
                <p>Attachment of a 20 kDa PEG molecule via a glycolinker to the O-glycosylation site at Thr 134 (that is, in the middle) of recombinant G-CSF</p>
            </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="sc_popup_01_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="References Title">References:</strong></p>
          <br />
          <div data-ag-editable="References List">
             <ol>
                <li>Neupogen速, Summary of Product Characteristics</li>
                <li>Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10(11):1235-1244</li>
                <li>Molineux G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27(12):1724-1734</li>
                <li>Layton JE et al. Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor. J Biol Chem 2001;276(39):36779-36787</li>
                <li>Tamada T et al. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proc Natl Acad Sci U S A. 2006;103(9):3135-3140</li>
                <li>Gregory SA et al. Commun Oncol 2010; 7:297-308</li>
                <li>Lipegfilgrastim EPAR 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002556/WC500148382.pdf [accessed December 2013]</li>
                <li>Lipegfilgrastim速, Summary of Product Characteristics</li>
             </ol>
          </div>
          <p data-ag-editable="References Bottom Copy"></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>